A phase I study targeting the APE1/Ref-1 DNA repair-redox signaling protein with the APX3330 inhibitor

被引：2
|
作者：
Kelley, Mark R. [1 ]
Shahda, Safi [1 ]
Lakhani, Nehal J. [2 ]
O'Neil, Bert [1 ]
Chu, Lincy [3 ]
Anderson, Amanda K. [3 ]
Wan, Jun [1 ]
Mosley, Amber L. [1 ]
Liu, Hao [1 ]
Messmann, Richard A. [4 ]
机构：
[1] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
[2] START Midwest, Grand Rapids, MI USA
[3] Epic Sci, San Diego, CA USA
[4] Apexian Pharmceut, Indianapolis, IN USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2019年 / 18卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-19-PR01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PR01
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Clinical trials targeting APE1/Ref-1 in pancreatic cancer with APX3330
    Kelley, Mark R.
    Shahda, Safi
    O'Neil, Bert H.
    Pearce, Homer
    Walling, Jackie
    CANCER RESEARCH, 2016, 76
  • [2] Inhibition of Ref-1/APE1 redox activity with APX3330 enhances Ref-1/APE1 protein unfolded conformation in human PDAC cells
    Mijit, Mahmut
    Babb, Olivia
    Gampala, Silpa
    Wireman, Randall
    Georgiadis, Millie M.
    Fishel, Melissa L.
    Kelley, Mark R.
    CANCER RESEARCH, 2022, 82 (12)
  • [3] Targeting Ref-1/APE1 pathway inhibition in pancreatic cancer using APX3330 for clinical trials
    Fishel, Melissa L.
    Logsdon, Derek P.
    Grimard, Michelle L.
    Supuran, Claudiu T.
    Zyromski, Nicholas
    Ivan, Mircea
    Kelley, Mark R.
    Shah, Fenil
    CANCER RESEARCH, 2016, 76
  • [4] Inhibition of APE1/Ref-1 redox activity with APX3330 blocks retinal angiogenesis in vitro and in vivo
    Jiang, Aihua
    Gao, Hua
    Kelley, Mark R.
    Qiao, Xiaoxi
    VISION RESEARCH, 2011, 51 (01) : 93 - 100
  • [5] A phase I study of the APE1 protein inhibitor APX3330 in patients with advanced solid tumors.
    Shahda, Safi
    Lakhani, Nehal J.
    O'Neil, Bert
    Rasco, Drew W.
    Wan, Jun
    Mosley, Amber L.
    Liu, Hao
    Kelley, Mark R.
    Messmann, Richard Adam
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] CTC enumeration and characterization as a pharmacodynamic marker in the phase I clinical study of APX3330, an APE1/Ref-1 inhibitor, in patients with advanced solid tumors.
    Chu, Lincy
    Anderson, Amanda K. L.
    Landers, Mark Andrew
    Wang, Yipeng
    Kelley, Mark R.
    Messmann, Richard Adam
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Efficacy study of APX3330, a Ref-1 redox inhibitor, and Gemcitabine in a mouse pancreatic ductal adenocarcinoma model
    McElyea, Kyle C.
    Jacobsen, Max H.
    Schmidt, Max
    Cheng, Huiwen
    Kelley, Mark R.
    Sandusky, George E.
    Fishel, Melissa L.
    CANCER RESEARCH, 2016, 76
  • [8] APE1/Ref-1 redox inhibitor APX3330 modulates choroidal endothelial cells by transcriptional regulation of NF-κB and STAT3 activity
    Qiao, Xiaoxi
    Li, Yue
    Liu, Xiuli
    Zhou, Tongrong
    Kelley, Mark
    Edwards, Paul
    Gao, Hua
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [9] APE1/REF-1: A DNA REPAIR PROTEIN WITH PLEIOTROPIC ACTIONS
    Tell, Gianluca
    ANTICANCER RESEARCH, 2008, 28 (5C) : 3513 - 3514
  • [10] Role of the multifunctional DNA repair and redox signaling protein Ape1/Ref-1 in cancer and endothelial cells: Small-molecule inhibition of the redox function of Ape1
    Luo, Meihua
    Delaplane, Sarah
    Jiang, Aihua
    Reed, April
    He, Ying
    Fishel, Melissa
    Nyland, Rodney L., II
    Borch, Richard F.
    Qiao, Xiaoxi
    Georgiadis, Millie M.
    Kelley, Mark R.
    ANTIOXIDANTS & REDOX SIGNALING, 2008, 10 (11) : 1853 - 1867
12345